The global aptamers market size was valued at USD 1.94 billion in 2022 and is expected to grow at a compounded annual growth rate (CAGR) of 24.54% from 2023 to 2030. 

Recent advancements in the generation, purification, and drug delivery for killing target cells have attracted the attention of many researchers towards aptamers due to the competitive advantages associated with them. Some of the advantages include small molecular size, low immunogenicity, low cost of manufacturing, and lesser side effects compared to antibodies; may fuel the R&D of novel aptamers, thereby driving market growth. Despite significant efforts, there are currently no highly effective treatments available against COVID-19 infections due to a large number of genetic mutations. However, biotechnological approaches appear to be promising in the treatment of COVID-19.

Consequently, nucleic-acid based aptamers & peptide aptamers might be effective against treating COVID-19 infection. Thus, various initiatives are being undertaken by the government to boost the R&D of novel treatment for COVID-19. For instance, in September 2020, the Department of Community & Economic Development awarded a contract of USD 320,000 to Aptagen LLC for the research and development of novel treatment for the COVID-19.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

Aptamers Market Report Highlights

• The nucleic acid aptamers segment dominated the market in 2022. The segment is set to grow at a rapid pace into areas such as therapeutics, diagnostics, research and development consumables, and biomarker discovery

• The research and development segment dominated the market in 2022 due to the growing interest of companies in aptamers; moreover, the rising awareness level coupled with favorable government initiatives are expected to stimulate the market growth of this applications segment during the study period

• The diagnostics segment is expected to be the fastest-growing segment during the forecast period due to the rising demand for aptamer-based diagnostic kits for the early diagnosis of diseases. For instance, in July 2021, SomaLogic and the CM Life Sciences announced the supply of 7,000-plex SomaScan Assay kits & SomaScan data to Beth Israel Deaconess Medical Center (BIDMC) for proteomics research

• North America dominated the market in 2022 due to the presence of key biopharmaceutical companies such as SomaLogic, IVERIC Bio, Inc., Aptagen LLC, Base Pair Biotechnologies, and their strategic initiatives for the development of new aptamers

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global live cell imaging market size was valued at USD 2.48 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.0% from 2024 to 2030.

• The global market for cell-free protein expression reached a value of USD 267.4 million in 2023 and is projected to grow at a CAGR of 8.6% from 2024 to 2030.

Aptamers Market Segmentation

Grand View Research has segmented the global aptamers market on the basis of type, application, and region:

Aptamers Type Outlook (Revenue, USD Million; 2018 - 2030)

• Nucleic Acid Aptamer

• Peptide Aptamer

Aptamers Application Outlook (Revenue, USD Million; 2018 - 2030)

• Diagnostics

• Therapeutics

• Research & Development

• Others

Aptamers Regional Outlook (Revenue, USD Million; 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o Germany

o UK

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• MEA

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.